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[Abstract] 
Kenny–Caffey syndrome (KCS) is a very rare dysmorphologic syndrome 
characterized by proportionate short stature, cortical thickening and medullary stenosis 
of tubular bones, delayed closure of anterior fontanelle, eye abnormalities, and 
hypoparathyroidism. The autosomal dominant form of KCS (KCS type 2: KCS2) is 
distinguished from the autosomal recessive form of KCS (KCS type 1: KCS1), which is 
caused by mutations of the tubulin-folding cofactor E (TBCE) gene, by the absence of 
mental retardation. In this study, I recruited four unrelated Japanese patients with typical 
sporadic KCS2, and performed exome sequencing in three patients and their parents to 
elucidate the molecular basis of KCS2. The possible candidate genes were explored by a 
de novo mutation detection method. A single gene, FAM111A (NM_001142519.1), was 
shared among three families. An identical missense mutation, R569H, was 
heterozygously detected in all the three patients but not in the unaffected family 
members. This mutation was also found in an additional unrelated patient. Although the 
function of FAM111A is not known, this study together with the independent 
simultaneous report from Switzerland would provide evidence that FAM111A is a key 
molecule for normal bone development, height gain, and parathyroid hormone 
development and/or regulation. 
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[Introduction] 
In 1966, Kenny and Linarelli first described an infant and his mother with 
transient hypocalcaemia, hyperphosphatemia, normal intelligence, ophthalmologic 
abnormalities, and severe proportionate short stature (1). Subsequently, Caffey reported 
the detailed radiographic findings of them (2). The distinctive findings of their 
roentgenogram were cortical thickening and medullary stenosis of tubular bones, and 
absent diploic space of the calvaria and delayed closure of the anterior fontanel. These 
typical radiographic characteristics of the patient analyzed in this study are shown in 
Figures 1 and 2. Since then, similar patients had been reported (3-7), and the 
constellation of these features was recognized as Kenny–Caffey syndrome (KCS).  
KCS is a very rare dysmorphologic syndrome characterized by severe 
proportionate short stature with adult heights of 121–149 cm, cortical thickening and 
medullary stenosis of tubular bones, delayed closure of the anterior fontanelle, eye 
abnormalities, and hypocalcaemia due to hypoparathyroidism (1-4). To date, KCS has 
been reported in approximately 70 cases (8). Other commonly reported features in KCS 
are characteristic facial features (prominent forehead, micrognathia, dental anomalies, 
relative macrocephaly, and microcephaly), prenatal growth retardation, growth hormone 
deficiency, anemia, mental retardation, impaired hepatic function, microorchidism and 
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immunological deficiency (9-17).  
Originally, KCS was thought to be transmitted in an autosomal dominant 
fashion (1, 2, 6, 7). In 1992, Franceschini et al. suggested that inheritance of KCS could 
be autosomal recessive by reporting female and male sibships with characteristic 
features of KCS born to normal consanguineous parents (7). In 1997, Khan showed 16 
children with KCS in six unrelated families born to healthy, consanguineous parents of 
Kuwaiti Bedouin ancestry (18). They presented with short stature, hypoparathyroidism, 
radiological finding of cortical thickening of tubular bones with medullary stenosis, 
absent relative macrocephaly and psychomotor retardation. Through these reports it has 
been known that KCS is occasionally transmitted as an autosomal recessive trait. 
Therefore, KCS is now classified into two types according to its clinical features and 
inheritance pattern. Classical cases have normal intelligence and are transmitted as an 
autosomal dominant trait or sporadically and are called KCS type 2 (KCS2) (7). Cases 
having mental and prenatal growth retardation and are transmitted as an autosomal 
recessive trait are called KCS type 1 (KCS1) (4, 16, 19).  
In Middle Eastern populations, the syndrome which had similar clinical 
findings to KCS1 had been reported and designated as Sanjad–Sakati syndrome (SSS) 
(20, 21). The cardinal features of this syndrome are congenital hypoparathyroidism, 
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mental retardation, facial dysmorphism, and growth failure. Thus, SSS is also known as 
Hypoparathyroidism–Retardation–Dysmorphism (HRD) syndrome. As SSS was a rare 
disorder and only found in Arab populations, it had been assumed that the disease was 
the result of homozygous inheritance of a recessive mutation from a common ancestor. 
In 1998, Parvari et al. reported that the gene for SSS was localized to 1q42–43 by 
homozygosity mapping for apparently unlinked kindreds (22). On the other hand, in 
1998, Diaz et al. performed a genome–wide search for linkage to the gene causing 
KCS1 using eight consanguineous Kuwaiti Bedouin kindreds (18), and identified a 
significant locus at chromosome 1q42–43 (23). They also found a conserved and rare 
haplotype at two short tandem repeat markers (STRs) by haplotype analysis of 
disease–bearing chromosomes. This finding suggested that there might be a common 
ancestral founder mutation in the Kuwaiti KCS1 families. In addition, as the critical 
region for KCS1 was identical to that of SSS (1q42–43), Diaz et al genotyped eight 
families with SSS from Saudi Arabia with STRs from the SSS/KCS1 critical region, and 
demonstrated that two syndromes shared an identical haplotype (24). These studies 
highlighted the possibility that two syndromes were caused by the same ancestral 
mutation. In 2002, The HRD/ Autosomal Recessive Kenny–Caffey syndrome 
Consortium eventually identified mutations of the tubulin-folding cofactor E (TBCE) 
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gene as the cause of KCS1 by studying 65 individuals from 34 pedigrees of Middle 
Eastern origin (25). TBCE encodes a molecular chaperone, and it is required for 
heterodimerization of α-tubulin with β-tubulin (25). Intriguingly, all patients of Middle 
Eastern origin had a deletion of 12 base pair homozygously in the second coding exon 
of TBCE. It showed the presence of a common founder mutation in this population (25). 
Although clinical features of KCS2 were similar to those of KCS1, a mutation of TBCE 
had not been reported in a patient with KCS2, and the cause of KCS2 remained 
unknown. 
For the past several decades, the gene underlying Menderian disorders had 
been identified through positional cloning, a process of meiotic mapping, physical 
mapping and candidate–gene sequencing from which the causative gene for KCS1 (i.e. 
TBCE) was elucidated (26, 27). Since 2005, next–generation DNA sequencing (NGS) 
technologies have become widely available and been applied for various purposes, 
reducing the cost of DNA sequencing by four orders of magnitude relative to Sanger 
sequencing (28, 29). NGS is a promising method having the potential to accelerate 
biological and biomedical research by enabling the comprehensive analysis of genomes. 
Moreover, since 2007 various technologies for capturing arbitrary subsets of a 
mammalian genome have been marvelously progressing at such a scale comparable to 
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that of massively parallel sequencing (30-34). The progress made us to perform the 
target sequencing of all protein–coding regions (i.e. whole–exome sequencing), which 
constitute less than 2% of the human genome. Figure 3 summarized the conceptual 
process of exome sequencing. Because most alleles that are known to underlie 
Menderian disorders disrupt protein–coding sequences (35), this technique is thought to 
be very promising for exploring causative genes for monogenic disorders (36-38). In 
fact, whole–exome sequencing combined with a filtering methodology was 
demonstrated as an approach to identify the gene underlying a Mendelian disorder using 
four patients’ samples (27). Subsequently, it was successfully used to determine the 
genetic basis of both recessive and dominant Mendelian disorders with a small number 
of affected individuals (39-44). Moreover, by using samples of parent-child trios, de 
novo mutations were found that were responsible for rare Menderian disorders as well 
as for genetically heterogeneous disorders such as intellectual disabilities, schizophrenia 
and autism (30, 45, 46). This kind of study design is most suitable for exploring a 
causative gene of a disease which occurs sporadically in most cases and was suspected 
to be transmitted dominantly (30). Looking back on KCS2, traditional disease–gene 
identifications had failed to identify the causative gene for KCS2, because KCS2 is 
extremely rare, with only five sporadic cases reported in Japan (47-50). Thus the 
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identification of allelic variants for KCS2 was fundamentally limited, and the cause of 
KCS2 had been unknown. 
In this study, I recruited four unrelated Japanese patients with typical sporadic 
KCS2 having normal intelligence and performed whole–exome sequencing in three 
unrelated parent-child trios to elucidate the molecular basis of KCS2. I hypothesized 
that KCS2 is caused by de novo mutations and built a de novo mutation detection 
pipeline to process the raw data from exome sequencing. Using this method, I found an 
identical de novo mutation in the “family with sequence similarity 111, member A” 
(FAM111A) gene (NM_001142519.1), R569H, in all four patients. While preparing for 
the report of my finding, another independent research group from Switzerland reported 
that KCS2 involved the FAM111A gene by following whole–exome sequencing of the 
patients (51). This and the reported independent studies provide the evidence that 
FAM111A is the cause of KCS2, and R569H is a hot spot mutation for KCS2.  
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[Subjects and Methods] 
Subjects 
Case 1 This 10-year-old girl (Figure 4, I-1) (47) was born at 40 weeks of gestation 
to non-consanguineous, healthy, Japanese parents. Polysyndactyly was noticed at birth. 
At three months of age, she was referred to a pediatric endocrinologist because of 
growth retardation. Her body length, body weight, and head circumferences were 55 cm 
(−2.5 SD), 5092 g (−1.8 SD), and 37.3 cm (0.2 SD), respectively. She was found to 
have liver dysfunction with a serum aspartate aminotransferase (AST) level of 227 U/l 
(reference range: 21–75) and serum alanine aminotransferase (ALT) level of 227 U/l 
(reference range: 11–69). Basal serum insulin-like growth factor 1(IGF-1), calcium (Ca), 
and phosphorus (P) levels were within normal limits. At the age of one year, 
hypocalcaemia was revealed. Her serum Ca, P, and intact parathyroid hormone (PTH) 
levels were 1.6 mmol/L (reference range: 2.1–2.4), 2.6 mmol/L (reference range: 
0.88–1.4), and 11 ng/L (reference range: 15–50), respectively, with a normal magnesium 
(Mg) level of 0.86 mmol/L (reference range: 0.74–0.90). Her serum 1,25(OH)2D level, 
serum alkaline phosphatase level, and urine Ca/creatinine ratio were within normal 
ranges. Brain computed tomography (CT) revealed calcification in the basal ganglia 
(Figure 5 A). She was diagnosed with primary hypoparathyroidism and was treated with 
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alfacalcidol [1α(OH)D3]. At two years of age, she was diagnosed with KCS2 based on 
clinical manifestations of proportionate short stature, cortical thickening and medullary 
stenosis confirmed by radioscopic study (Figure 5 B), macrocephaly with delayed 
closure of the anterior fontanelle, eye abnormalities (hypermetropia and 
pseudopapilledema), and normal intelligence. Magnesium oxide was administered 
because of a low serum Mg level (below 0.62 mmol/L) at three years of age. Growth 
hormone therapy was initiated at nine years of age on the basis of severe growth 
hormone deficiency (GHD). Her height and weight at the age of 10 years 3 months were 
110.8 cm (-4.2SD) and 32.5 kg (-0.2 SD), respectively.  
Case 2 This 16-year-old boy (Figure 4, II-4) (48) was born at 41 weeks of gestation 
to non-consanguineous, healthy, Japanese parents. When he was 23 days old, he had a 
generalized convulsion because of hypocalcaemia. At this time, his serum Ca, P, Mg, 
and intact PTH levels were 1.5 mmol/L, 3.1 mmol/L, 0.74 mmol/L, and undetectable, 
respectively. T cell subset was normal. He was treated with alfacalcidol on the basis of a 
diagnosis of primary hypoparathyroidism. Magnesium sulfate was added because of his 
low serum Mg level at the age of one year. He suffered repeated bouts of acute otitis 
media until the age of two years. His serum IgG level was within the normal range. At 
three years and one month, his height, weight, and head circumference were 77.9 cm 
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(−4.4 SD), 9.9 kg (−2.7 SD), and 47.4 cm (−1.5 SD), respectively. He had normal 
intelligence for his age. He was diagnosed with KCS2 based on clinical findings of 
proportionate short stature, medullary stenosis revealed by radiography, a widely open 
anterior fontanelle (Figure 6 A, skull radiograph at nine years), and hypermetropia. He 
also suffered severe atopic dermatitis after normalization of his serum Ca levels. He had 
mild GHD and was treated with growth hormone, but no effect was observed. His 
growth chart is shown in Figure 6 B. His height at the age of 16 years was 120.6 cm 
(-8.2SD). 
Case 3 This 22-year-old woman (Figure 4, III-9) (49) was born at 40 weeks of 
gestation to non-consanguineous, healthy, Japanese parents, following an uneventful 
pregnancy. At one month, she had an episode of generalized convulsions because of 
hypocalcaemia. At this episode, her serum Ca, P, Mg, and intact PTH levels were 1.3 
mmol/L, 2.9 mmol/L, 0.49 mmol/L, and undetectable, respectively. Oral alfacalcidol 
administration was started on the basis of a diagnosis of primary hypoparathyroidism. 
At the age of five years one month, she was referred to another hospital. Her height was 
84.2 cm (−5.3 SD), and her weight was 12.2 kg (−2.2 SD). She had normal intelligence. 
Brain CT revealed fine calcification in the basal ganglia. Based on clinical 
manifestations of proportionate short stature, medullary stenosis of the long bones 
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typical of KCS, a 11 cm opening of her anterior fontanelle, normal intelligence, and 
hypermetropia, she was diagnosed with KCS2. The patient was started with a 
combination therapy of vitamin D and magnesium sulphate. Since her short stature did 
not improve with this therapy, GH therapy was initiated at the age of 7 years 5 months 
on the basis of mild GHD, and had been continued till 17 years of age. Meanwhile 
gonadotropin releasing hormone analog was concomitantly administered to delay her 
bone maturation. Her height and weight at 22 years were 134cm (-4.5 SD) and 34kg, 
respectively. Figure 7 shows her radiograph at 14 years of age. 
Case 4 This 38-year-old man (Figure 4, IV-13) (50) was born at 40 weeks of 
gestation to non-consanguineous, healthy, Japanese parents, following an uneventful 
pregnancy. At eight days of age, he had a generalized convulsion, and hypocalcaemia 
(0.75 mmol/L) and hypomagnesemia (0.18 mmol/L) were detected. The convulsion was 
controlled by intravenous administration of Ca gluconate and magnesium sulfate until 
he was 15 days old. At four years of age, he again had an episode of generalized 
convulsion because of hypocalcaemia. At this episode, his serum Ca, P, and intact PTH 
levels were 1.2 mmol/L, 2.6 mmol/L, and undetectable, respectively. He was diagnosed 
with primary hypoparathyroidism, and oral alfacalcidol and Ca lactate administration 
were started. He suffered repeated acute otitis media during infancy and was affected 
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with empyema and bacterial meningitis at four years of age. Hypogammaglobulinemia 
was found, and he was administered gamma globulin intermittently. At 12 years of age, 
he was referred to another hospital for further investigation. His height was 99 cm (−6.3 
SD), and his weight was 16.2 kg (−3.3 SD). He had normal intelligence with an 
intelligence quotient score of 105. Brain CT revealed fine calcification in the basal 
ganglia. Based on clinical manifestations of proportionate short stature, medullary 
stenosis of the long bones, a 4.21.8 cm opening of his anterior fontanelle, and eye 
abnormalities (hypermetropia, amblyopia, and pseudopapilledema), he was diagnosed 
with KCS2. Mg loading and Ca restriction tests revealed that his hypoparathyroidism 
was secondary to hypomagnesemia. The patient was then changed from vitamin D and 
Ca lactate to magnesium sulfate treatment, which successfully corrected his serum Ca 
levels. His height at 37 years was 140cm (-5.3 SD). 
I recruited these four Japanese patients with clinically diagnosed typical 
sporadic KCS2. Table 1 summarizes the clinical characteristics of the four patients. I 
obtained peripheral blood samples from all four patients, together with those of nine 
unaffected parents or siblings, with informed consent for DNA analysis. The study was 
performed with the approval of the Ethics Committee of The University of Tokyo 
(approved number: 2010-G3060) and of each institution where the samples were 
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collected, and conducted in accordance with the Declaration of Helsinki. Genomic DNA 
was extracted from peripheral white blood cells of the patients and family members 
using a QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany). Healthy Japanese 
volunteers were recruited and DNA was extracted with informed consent. 
Exome sequencing 
Exome sequences were enriched using a TruSeq Exome Enrichment Kit 
(Illumina, San Diego, CA, USA) from 1 μg of genomic DNA, according to the 
manufacturer’s instructions. The captured DNA samples were subjected to massively 
parallel sequencing (100 bp paired-end reads) on an Illumina HiSeq2000 sequencing 
system (Illumina). An average of 95 million reads of the sequence data was obtained for 
each individual. On an average, 98.50% of the total bases were mapped to the reference 
genome with a mean coverage of 140.5×, which encompassed 91.94% of the targeted 
regions with coverage >10× (Table 2). I built an original pipeline to process the raw 
data from exome sequencing under the hypothesis that KCS2 is caused by de novo 
mutations (Figure 8). The Burrows-Wheeler Aligner (BWA) package (52) and 
SAMtools (53) were used as default settings for alignment of raw reads and detection of 
single-nucleotide variants (SNVs) and indels. Subsequently, SNVs and indels were 
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filtered with three trio samples (i.e., pedigrees I, II, and III) (Figures 4). I extracted both 
homo/heterozygous non-synonymous coding variants, which were called in the proband, 
and filtered these candidates using the following three steps: 
Step 1: Using candidate de novo mutations that are homozygous references in both 
parents and are supported by 10 or more high quality reads at the mutated sites for every 
trio member. 
Step 2: Using reliable homozygous references in each parent such that the likelihood of 
heterozygosis, nCi (1/2)
i (1/2)n-i, is less than that of homozygosis, nCi 
(999/1000)i(1/1000)n-i , where the average error rate is assumed to be 1/1000, n 
represents the number of total reads, and i is the number of reads consistent with the 
reference. One may have an impression that this condition does not often hold true; 
however, I often observed cases that violated this condition, especially when the 
reference base was mutated into one of the other three bases with an almost equal 
probability. 
Step 3: Using reliable de novo mutations of the proband such that the number of 
alternative allele reads was at least 30% among the total reads, which is the condition 
proposed in a recent report (54).  
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Sanger sequencing 
Sanger sequencing was performed to detect TBCE (KCS1) and validate the 
presence of each variant detected by exome sequencing in patients with KCS2 and the 
absence of each in the genomes of the parents and siblings. The entire coding region and 
exon-intron boundaries of TBCE and FAM111A were amplified from genomic DNA by 
polymerase chain reaction (PCR) using the designed PCR primers (Tables 3 and 4, 
respectively). Subsequently, sequencing was performed with PCR products using an 
ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied 
Biosystems, Foster City, CA, USA) and the forward and reverse primers used for PCR 
amplification. Direct sequencing in both directions was performed on an autosequencer 
(PE Applied Biosystems 3130×1, Genetic Analyzer). 
FAM111A mRNA expression analysis 
Total RNA was prepared using ISOGEN reagent (Nippon Gene, Osaka, Japan), 
according to the manufacturer’s instructions, from peripheral white blood cells of the 
patients and family members. Total RNA (4 μg) was used to synthesize cDNA with the 
SuperScript Preamplification System for first strand cDNA synthesis (Life Technologies, 
Rockville, MD, USA). mRNA levels were measured using an ECO real-time PCR 
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system (Illumina) and KAPA SYBR Fast qPCR Kit (Kapa Biosystems, Woburn, MA, 
USA) using the following primer pairs: FAM111Ae5-2F and FAM111Ae5-2R; 
FAM111Ae5-3F and 5′-CCTCATCACTCATCATTTCTACATCC-3′; GAPDH, 5′- 
GAAGGTGAAGGTCGGAGTC-3′ (F) and 5′- GAAGATGGTGATGGGATTTC-3′ (R). 
The cycle conditions were 95 °C for 1 min followed by 45 cycles of 95 °C for 5 s, 60 °C 
for 30 s. After completion of the reaction cycles, melting curves were obtained by 
heating the samples from 55 °C to 95 °C. The specificity of the primers was confirmed 
by the presence of a single peak in the melt curve generated for each gene. The relative 
mRNA level was calculated using an arithmetic formula based on the difference 
between the threshold cycle of a given target cDNA and that of an endogenous reference 
cDNA. Direct sequencing of the reverse-transcribed PCR (RT-PCR) products was 
performed by Sanger sequencing as for DNA samples. 
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[Results] 
I first confirmed by Sanger sequencing that none of the four patients had TBCE 
mutations. This finding, together with the fact that all the patients were of normal 
intelligence, distinguishes these patients from patients with KCS1.  
I hypothesized that these sporadic cases may be caused by de novo mutations in 
novel nonsynonymous coding variants. Whole exome sequencing was performed for 
three patients (I-1, II-4, and III-9, Figure 4) and their parents (I-2, I-3, II-5, II-6, III-10, 
and III-11, Figure 4). Statistical data of exome sequencing experiments are shown in 
Table 2. The candidate variants were selected according to the processes described in 
the Methods section based on the de novo mutation detection pipeline designed in the 
present study (Figure 8). Table 5 summarizes the results of filtering to detect candidate 
genes for KCS2. To select variants as candidate mutations for KCS2, variations that 
caused amino acid substitution were extracted, which resulted in 11,024 (pedigree I), 
10,828 (pedigree II), and 11,020 (pedigree III) SNVs and indels. After three filtering 
steps, five (pedigree I), five (pedigree II), and six (pedigree III) SNVs were identified. 
Among the candidate genes filtered using the three aforementioned filtering steps, only 
one single gene, FAM111A (NM_001142519.1), was shared among all three families 
(Figure 9). Sanger sequence analysis of all exons of FAM111A confirmed an identical 
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c.1706G>A heterozygous mutation in exon 5 in all three patients (Figures 10). This 
mutation is predicted to result in substitution of arginine to histidine in codon 569 
(R569H). None of the unaffected family members had this mutation, indicating that 
R569H was a de novo mutation. This mutation was also found in an additional unrelated 
patient (IV-13, Figure 10). 
R569H is not present in 373 Japanese healthy control subjects of inhouse 
exome database, and not in another 100 alleles from 50 unrelated healthy Japanese 
individuals by Sanger sequencing. It was also not found in the Japanese 
single-nucleotide polymorphism (SNP) control database established by the National 
Bioscience Data Base Center that has one million genome–wide SNPs of 700 
samples (http://gwas.biosciencedbc.jp/snpdb/snp_top.php), nor among 6500 samples 
listed on the exome variant server (http://evs.gs.washington.edu/EVS/), implying that 
the minor allele frequency is less than 0.01% in these data. However, one SNP was 
found in the 1000 Genomes database at R569 (rs184251651), which results in 
substitution to “cysteine” (minor allele frequency 0.1%).  
I assessed the functionality of the R569H mutation using the Sorting Intolerant 
From Tolerant (SIFT) (http://sift.jcvi.org) and Polymorphism Phenotyping 2 
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(PolyPhen2) (http://genetics.bwh.harvard.edu/pph2) tools, by homology modeling and 
threading. These in silico studies predicted R569H as “tolerated” and “benign,” 
respectively (Figure 11).  
I analyzed the expression levels of FAM111A mRNA in peripheral white blood 
cells by real-time PCR. FAM111A expression levels in the patients were comparable 
with those in unaffected family members and normal controls (Figure 12). I also found 
that mutant and wild-type FAM111A were equivalently expressed in the patients, which 
were identified by sequencing the RT-PCR products (Figure 13). 
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[Discussion] 
In the present study, I identified FAM111A as the gene responsible for KCS2 by 
applying an exome sequencing strategy, and I identified a heterozygous identical de 
novo FAM111A mutation, R569H, in four Japanese patients with KCS2. While preparing 
for this manuscript, another independent research group from Switzerland reported 
similar findings following whole exome sequencing of the patients with KCS2 or 
gracile bone dysplasia under the hypothesis that these two syndromes might be allelic 
disorders of different severity (51). They found that all five clinically diagnosed KCS2 
patients and all five clinically diagnosed gracile bone dysplasia patients had de novo 
FAM111A mutations by using different strategy for detecting de novo mutations. Most 
interestingly, four of the five patients with KCS2 from different countries had the same 
R569H mutation as detected in the patients analyzed in this study (Figure 14). Four 
pedigrees investigated in the present study are unrelated to each other and live in 
different areas in Japan. Moreover, the parents of the three patients did not have the 
mutation, suggesting that this recurrent mutation was caused by sporadic mutation. As 
these two independent and simultaneous studies were performed with different filtering 
methodologies for detecting de novo mutations causative for KCS2, these studies 
confirm that FAM111A is the causative gene for KCS2, and R569H is the hot spot 
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mutation of KCS2, although both studies had not analyzed the function of FAM111A. 
FAM111A encodes a protein consisting of 611 amino acids, and there is 
homology to trypsin-like peptidases in its carboxy-terminal half (Figure 14). The 
catalytic triad specific to such peptidases is conserved (55). At present, the function of 
the protein is largely unknown. According to the human protein atlas 
(http://www.proteinatlas.org/ENSG00000166801/normal), transcriptional expression of 
FAM111A is ubiquitous. It is expressed in the parathyroid gland and bone, but the 
expression levels are similar to those in other tissues. FAM111A has 35% amino acid 
homology to FAM111B, a paralog located on 11q12.1 at a distance of only 16 kb from 
FAM111A. The functions of FAM111A and FAM111B are largely unknown. Recently, 
FAM111A have been reported that it functions as a host range restriction factor and is 
required for viral replication and gene expression by interacting with Simian Virus 40 
large T (LT) antigen (55). In addition, they reported that FAM111A mRNA and protein 
levels were regulated in a cell cycle-dependent manner with the lowest expression 
during the G0 or quiescent phase and peak expression during the G2/M phase (55). 
Another recent report revealed that variants in the region including FAM111A and 
FAM111B were associated with prostate cancer (56). However, the clinical course of 
disease in the four patients investigated in this study revealed neither increased viral 
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infections nor carcinogenesis up to early adulthood. 
In silico analyses suggested that the de novo mutation (R569H) would not 
significantly affect the function of FAM111A (Figure 11). I also found that the mutant 
FAM111A mRNA was expressed similarly to the wild-type in peripheral blood cells 
(Figure 12). This raises the question of how this mutation causes KCS2. I hypothesize 
that this mutation does not cause loss of function of the protein but rather modulates its 
peptidase activity for a particular target peptide in a mutant-specific way. Another 
possibility is that FAM111A functions with some physiological partner(s) and the 
disease occurs as a result of specific modulation of this putative network. This may fit 
the observation that FAM111A is regulated in a cell-dependent manner and interacts 
with the LT C-terminal region (55). I speculate that one of the candidate partner proteins 
is TBCE because KCS1 and KCS2 share distinctive phenotypic features: skeletal 
dysmorphic features and primary hypoparathyroidism.  
Some diseases are caused by specific mutations of a single gene. Some 
mutations may cause a gain-of-function effect, as in achondroplasia or 
McCune–Albright syndrome (57, 58), while others have an unknown function, as in 
Caffey syndrome caused by mutations in collagen type1 alpha 1 (COL1A1) gene (59) or 
in several diseases related to fibroblast growth factor receptor 3 (FGFR3) gene. In this 
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study, I found that a specific mutation (R569H) of FAM111A would lead to KCS2. 
Intriguingly, one SNP was found in the 1000 Genomes database at R569 (rs184251651), 
which results in substitution to “cysteine.” This SNP has been reported to have minor 
allele frequency of 0.1% (only one allele) and is not validated. Moreover, the absence of 
the SNP in 6500 samples in the exome variant server suggests a possibility of 
sequencing error in the database. Nevertheless, it might be speculated that a specific 
change to “histidine” may lead to an unidentified function of this protein resulting in 
KCS2, which is not caused by other amino acids. This hypothesis will be supported by 
the fact that this amino acid is not well conserved among various species (Figure 15).  
It is reported that 95% and 97% of KCS1 cases had prenatal and postnatal 
growth retardation, and mental retardation, respectively (10). In contrast, most of the 
reported KCS2 patients, including our patients with FAM111A mutations, had normal 
birth weight and length, and normal intelligence (Table 1) (51). These phenotypic 
differences between KCS1 and KCS2 suggest that the FAM111A mutation does not 
affect bone development and height gain in the fetus but become important postnatally. 
It also suggests that the FAM111A mutation does not affect mental development. Now 
that FAM111A has been identified as a causative gene for KCS2, further studies on the 
physiological function of FAM111A and TBCE should be performed to uncover the 
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phenotypic differences between these two types (Figure 16). 
There are several human diseases, as well as mouse models of 
hypoparathyroidism, caused by aberrations in the cascade of genes indispensable for the 
development and regulation of the parathyroid gland (60, 61). To date, FAM111A is not 
known to relate to any of these genes. There have been only a few reports describing the 
pathophysiology of hypoparathyroidism in KCS. Absence of the parathyroid glands has 
been reported in some patients with KCS2 and KCS1 (62, 63). In contrast, some 
patients do not have hypoparathyroidism from early infancy, suggesting the presence of 
some parathyroid gland as in the patient I-1 (4, 17). Furthermore, hypoparathyroidism 
may be secondary to hypomagnesemia as in the patient IV-13. Considering the fact that 
all of four patients investigated in the present study as well as another reported KCS2 
case had hypomagnesemia (4), FAM111A might be involved in magnesium homeostasis. 
Although further investigation is necessary to reveal the cause of hypoparathyroidism in 
KCS2, this study shows that a new gene, FAM111A, is indispensable for PTH 
development and/or regulation. 
KCS is a very rare syndrome that has been reported only in approximately 70 
patients in the literatures (8), although KCS2 is an autosomal dominant disease with 
normal intelligence. On the other hand, achondroplasia occurs in between one in 10,000 
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and one in 30,000 livebirths, in which more than 95% of patients have the same 
mutation in FGFR3, G380R, and more than 80% of these patients are sporadic (64). As 
compared to the occurrence rate of achondroplasia, the rarity of KCS is outstanding. 
One possible explanation for this rarity is that patients with KCS may have gonadal 
hypofunction. To date, inheritance from a father-to-child has not been described 
regardless of an equal sex ratio of affected individuals reported in the literatures (9, 65), 
while the first reports of KCS was two patients which was thought to be mother-to-child 
transmission (1). In addition, reported pubertal or adult-age male patients with KCS had 
findings suggestive of microchidism or infertility (5, 6, 11, 17, 62). However, the 
pathogenesis of the microchidism seen in male patients with KCS remains unknown. 
There is only one report about this matter that hormonal investigations of male patients 
with KCS and microchidism showed normal sex hormones except for elevations of the 
follicle-stimulating hormone, and the histology of testes revealed Leydig cell 
hyperplasia but otherwise normal anatomy (11). It should be noted that micropenis was 
reported in four fifth FAM111A mutation positive males of the same allelic condition 
with KCS2, gracile bone dysplasia, by the Switzerland group (51). Although further 
studies will be necessary to establish the pathogenesis of male gonadal hypofunction, 
FAM111A may be important in the development and function of male genitalia. Another 
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possible explanation is that some KCS patients would not be diagnosed as KCS. 
Recently, Guo et al. identified a KCS patient with a R569H mutation of FAM111A from 
14 children with severe short stature of unknown etiology by whole–exome sequencing 
(66). It is of note that the patient had not been suffered from hypoparathyroidism. This 
report highlighted the possibility that there may be more patients with KCS in short 
stature children of unknown etiology. As the genetic background of KCS2 was 
elucidated in this study, there might be the possibility that more patients with KCS 
would be reported.  
Effective treatment for short stature in patients with bone disease is scarce, 
although our understanding of molecular mechanism for bone growth has been 
gradually growing. This is partly because of a lack of efficient method for screening and 
testing potential drugs (67). Recently, Yamashita et al. reported that statin treatment 
improved FGFR3 skeletal dysplasia dwarfism by developing a human-disease based 
system for screening potential drugs (68). They established a cell-based model of 
impaired bone growth by using induced pluripotent stem (iPS) cells. Considering recent 
dramatic advances in the technology of iPS cells, this method would allow us to screen 
potential drugs for treating short stature of another bone disease like KCS. In addition, it 
is notable that short stature in patients with KCS is proportionate, which implied that the 
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cell-based model of KCS might be very promising for exploring drugs effective for not 
only tubular bones but also other bones. I believe that in the long run, my finding would 
be contributing to discovering new drugs for short stature. 
TBCE mutation causes both KCS1 and SSS, and FAM111A mutation causes both 
KCS2 and gracile bone dysplasia (8, 25, 51, 69). Clinical features of these syndromes 
and its causative genes were summarized in Figure 17. As these syndromes share 
characteristic three features (growth retardation, hypoparathyroidism, and skeletal 
defects) and causative genes had been identified (Figure 17), I propose that these 
syndromes should be designated as Kenny–Caffey related syndromes. However, some 
patients with these syndromes do not have a mutation in these responsible genes. This 
fact suggested that there may be other syndrome which could be included in this entity, 
and there may be other gene which would be responsible for this entity. Genetic 
analyses of additional patients in this entity and further investigation for exploring other 
responsible gene should be needed to elucidate the whole picture of this entity. 
As the function of FAM111A remains largely unknown at present, I would like to 
clarify its function in several methods. First, I will study the molecular mechanism of 
cartilage proliferation and differentiation by using some cell lines like ATDC5. With 
these studies, I would be able to find the putative network related to FAM111A. Second, 
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I will make transgenic mice for the recurrent mutation of FAM111A and study 
expressions of FAM111A and its putative related genes in several tissues. If I could 
make transgenic mice that had phenotypes of KCS2, I might be able to elucidate many 
unidentified function of FAM111A by investigating tissues of the mice. Third, I will 
develop the above mentioned cell-based model of KCS by using iPS cells. With this 
method, I might discover new drugs for improving phenotypes of KCS2. Through these 
in vitro and vivo studies, I would like to elucidate the function of FAM111A one by one 
in the near future. 
In conclusion, my finding that all four Japanese KCS2 patients analyzed in this 
study have the same de novo mutation (R569H) of FAM111A indicates that KCS2 is 
caused by a heterozygous mutation of FAM111A, and R569H is the hot spot mutation in 
patients with KCS2. Although the function of FAM111A is largely unknown, this study 
provides evidence that FAM111A is a key molecule for normal bone development, 
height gain, and PTH development and/or regulation. My finding further creates a new 
research area in the fields associated with shared phenotypic features in KCS and 
different phenotypes between KCS1 and KCS2.  
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[Tables] 
Table 1: Clinical characteristics of four unrelated Japanese patients with sporadic 
Kenny-Caffey syndrome type 2 (KCS2) 
Patient number I-1 II-4 III-9 IV-13 
Gender Female Male Female Male 
Birth weight 3,094 g (0.3 SD) 2,882 g (-0.4 SD) 2,750 g (-0.5 SD) 2,900 g (-0.3 SD) 
Birth length 47.5 cm (-0.4 SD) 50.0 cm (0.5SD) 46 cm (-1.1 SD) 46 cm (-1.4 SD) 
Hypoparathyroidism Yes Yes Yes Yes 
Hypomagnesemia Yes Yes Yes Yes 
Short stature Yes Yes Yes Yes 
Mental retardation No No No No  
Tubular bone finding1) Yes Yes Yes Yes 
Anterior fontanelle2) Yes Yes Yes Yes 
Eye abnormalities Hypermetropia, 
Pseudopapilledema 
Hypermetropia Hypermetropia Hypermetropia , 
Amblyopia, 
Pseudopapilledema 
GHD3) Severe GHD Mild GHD No No 
Age at diagnosis 2 years 4 years 5 years 12 years 
Age at follow-up 10 years  16 years  22 years 38 years 
Height at last follow-up 110.8 cm 
(-4.2SD) 
120.6 cm 
(-8.2 SD) 
134 cm  
(-4.5 SD) 
140cm 
(-5.3 SD) 
Other features Infantile liver 
dysfunction, 
Polysyndactyly, 
anemia  
Severe atopic 
dermatitis 
Hypothalamic 
amenorrhea 
Humoral 
immunodeficiency 
1) Cortical thickening and medullary stenosis of the tubular bones,2) Delayed closure of 
anterior fontanelle, 3) Growth hormone deficiency 
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 Table 2: Statistics of exome sequencing experiments in this study 
 
 
 
  
Sample 
number 
Reads Mapped reads Mapping 
Rate (%) 
Target coverage 
>10x 
Coverage(x) 
I-1 100,588,416 98,978,316 98.40 92.01 147.66 
I-2 120,057,198 118,622,122 98.80 93.51 177.03 
I-3 123,580,080 122,049,696 98.76 93.52 182.15 
II-4 102,877,966 101,492,454 98.65 92.63 151.41 
II-5 78,363,868 77,202,661 98.52 91.36 115.69 
II-6 88,778,654 87,327,784 98.37 92.07 130.88 
III-9 92,622,462 91,125,885 98.38 91.92 136.89 
III-10 80,820,926 79,540,594 98.42 90.88 119.42 
III-11 69,884,892 68,675,010 98.27 89.60 103.15 
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Table 3: Primers and PCR conditions used to amplify the coding region of TBCE  
Primer name Sequence 5’-3’ Product size  Annealing temperature 
TBCEe1F GTCATCCCAGGTTTCAGCAC 361 bp 60 °C 
TBCEe1R GGCTCTGGCAATCTGGGAAG 
TBCEe2F TTCTTATCAGTGTTGTATTTTTCTTCC 285 bp 60 °C 
TBCEe2R GCTTACACAGAAACAGCTGCAA 
TBCEe3F ACTTGTCCATTCCCTCCTCC 302 bp 60 °C 
TBCEe3R TTCTTCCTCTCCATCCCTCC 
TBCEe4F TTTATGGCCTTTCTTGGTGG 353 bp 60 °C 
TBCEe4R ACCAGTTTAGGAGCAAAGTC 
TBCEe5F AATTTGGGTGGTGGTTACTG 332 bp 60 °C 
TBCEe5R AAGGAAGTTGTCAAGACTGG 
TBCEe6F GCTCATGCTCTGGAATTAAG 335 bp 60 °C 
TBCEe6R TCAGCCTGAGTAATTCCTTC 
TBCEe7F ACCCAGATTGTTGCTTTC 402 bp 60 °C 
TBCEe7R TGAGATAGGACATGGATTTC 
TBCEe8F TGAGGCACTTGTTTGCTG 347 bp 60 °C 
TBCEe8R TCTAATTTGTGAAGGCAATG 
TBCEe9F AGGGACCACTCAGGTTG 357 bp 60 °C 
TBCEe9R ATTCCATCATTGTTACCACG 
TBCEe10-11F AAGAGTTCACTTTGCATGTC 465 bp 60 °C 
TBCEe10-11R AGAAGGAACCTCCAAACTC 
TBCEe12F GGGACATGCTTTCCTGTTG 345 bp 60 °C 
TBCEe12R AGCCTCCCAAAGTGCTG 
TBCEe13F GCATGTGCTATGGAGGAAG 372 bp 60 °C 
TBCE e13R CAAGAAGCCCAGGAAAGG 
TBCEe14F TCTCTGGACGCTTACCTATC 358 bp 60 °C 
TBCEe14R ATCACACCACTGCACTCC 
TBCEe15F GGCCATCTGTTGATGTGTG 249 bp 60 °C 
TBCEe15R TCTGAGGTCCACACTTTGAG 
TBCEe16F TGCAATGATACTGTGGTCTC 326 bp 60 °C 
TBCEe16R CCAGGCAGTAGCTTACC 
TBCEe17F TTAAGGGTAAGCTACTGCCTG 633 bp 60 °C 
TBCEe17R CCCAAGTTTAAGGGACATTTC 
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Table 4: Primers and PCR conditions used to amplify the coding region of FAM111A. 
Primer Sequence 5’-3’ Product size  Annealing temperature 
FAM111Ae4F AGGGAGAGCAAGGTTGGAGC 530 bp 54 °C 
FAM111Ae4R GAGTGTGCCTGAACTAAACGTGC 
FAM111Ae5-1F AAAGACTCGGGTTGCATTCAG 665 bp 54 °C 
FAM111Ae5-1R AGAAATCTGCCATCCTTGCAC 
FAM111Ae5-2F CAGGCAGGACAAAGCATCG 700 bp 50 °C 
FAM111Ae5-2R ACCAATTATGGTTGCCCACTTAC 
FAM111Ae5-3F TGGGTACTTATTCTGGGACAGTG 899 bp 54 °C 
FAM111Ae5-3R GCCTGGCAGATAGGAAATGG 
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Table 5: The results of filtering for detecting candidate genes for KCS2 
Pedigree Possible SNVs 
and indels 
After filtering step 
1 
After filtering step 
2 
After filtering step 
3 
 I  11,024 118 16 5 
II 10,828 157 13 5 
III 11,020 93 9 6 
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[Figures] 
 
 
Figure 1: Radiographs of a patient with Kenny-Caffey syndrome. 
 (A) Upper limbs, (B) Lower limbs  
Cortical thickening and medullary stenosis of tubular bones were detected. 
(A) 
(B) 
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Figure 2: Radiographs of the skull of an 18-year old patient with Kenny-Caffey 
syndrome. 
  Anterior fontanelle is open, and the calvaria is a thin sclerotic plate without a 
diploic space. Dental anomalies were also detected. 
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Figure 3: Conceptual diagram of an exome sequencing. 
Genomic DNA is fractionated to fragment templates. (Dark blue fragments indicated 
exons.) These fragments are hybridized to adaptors which were designed around exons 
(pink fragments termed “bait”). With these fragments, biotin-streptavidin-based 
pulldown is performed. It is followed by amplification and massively parallel 
sequencing of the enriched and amplified library. Finally, the mapping and calling of 
candidate causal variant were explored. 
This figure was drawn by referencing and modifying the review by Bamshad MJ, et al 
(30). 
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Figure 4: Four pedigrees analyzed in this study. 
A black symbol represents the proband, a square indicates a male, and a circle shows a 
female. 
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Figure 5: Radiographic studies of case 1(proband I-1) 
A. Brain computed tomography  
The arrowheads indicate calcification in the basal ganglia. 
B. Radiograph at diagnosis 
Cortical thickening and medullary stenosis are evident. The object shown in the right 
leg is used for fixing a peripheral catheter. 
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Figure 6: Radiographic study and growth chart of case 2 (proband II-4). 
A. Radiograph of case 2 at nine years.  
It is of note that the anterior fontanelle is open. 
B. Growth chart of case 2 superimposed on the standard growth chart for a 
Japanese boy.  
Black circles indicate the patient’s height and black squares indicate his weight. 
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Figure 7: Radiographic study of case 3 (proband III-9). 
Cortical thickening and medullary stenosis can be observed. 
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Figure 8: Pipeline for the detection of novel de novo mutations. 
This pipeline was used to identify pathogenic mutations of Kenny–Caffey syndrome 
type 2. All genetic variants detected by exome sequencing were sequentially filtered 
through the pipeline described in the Methods section. BWA: Burrows-Wheeler Aligner 
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Figure 9: Candidate genes for KCS2 detected after the filtering method established 
in this study. 
After using the three filtering steps mentioned in the text, several candidate genes were 
detected. Among these genes, only one single gene, FAM111A (NM_001142519.1), was 
shared among all three families. chr: chromosome number; pos: position; ref: reference 
nucleotide; alt: altered nucleotide; db SNP: data base single nucleotide polymorphism    
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Figure 10: Four pedigrees analyzed in this study, showing the chromatograms of 
Sanger sequencing reactions of the FAM111A mutation in patients and family 
members.  
Data were obtained by Sanger sequencing during the confirmation process. All 
mutations were checked by bidirectional sequencing. In each pedigree, a black symbol 
represents the proband, a square indicates a male, and a circle shows a female. In the 
chromatogram, black letters indicate the wild-type nucleotide sequence. Nucleotides in 
red indicate mutations. R569H was identified in all probands but not in any of the 
unaffected family members. 
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Figure 11: The result of in silico analyses about R569H, the hot spot FAM111A 
mutation for Kenny–Caffey syndrome type 2. 
A. SIFT 
  SIFT analysis predicted R569H as tolerated. 
B. PolyPhen2 
PolyPhen2 analysis predicted R569H as benign with a score of 0.143. 
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Figure 12: Relative expression levels of FAM111A. 
Relative expression levels were calculated by the comparative CT method. II-4 represent 
the patient with KCS2 (case2), and II-5 and II-6 are his parents. Fold changes were 
relative expression levels of normal control. GAPDH gene expression was used as an 
endogenous control. Data were expressed as mean ±SD (n= 3). FAM111A expression 
level in the patient was comparable with those in unaffected family members and 
normal control. 
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Figure 13: Direct sequencing of the RT-PCR product of II-4 
Direct sequencing of the RT-PCR product of II-4 was performed by Sanger sequencing 
as for DNA samples. This analysis identified that the mutant and wild-type FAM111A 
were equivalently expressed in the patient. 
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Figure 14: Mutations identified in two independent studies. 
FAM111A encodes a protein consisting of 611 amino acids, and its carboxy-terminal half 
has homology to trypsin-like peptidases. However, the function of FAM111A is largely 
unknown at present.  
Four of the five patients with KCS2 from different countries identified in another 
independent research group from Switzerland had the same R569H mutation as detected 
in the patients investigated in the present study. Therefore, my study together with 
another study from Switzerland group confirmed that FAM111A is the causative gene 
for KCS2, and R569H is a hot spot mutation of KCS2. 
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Figure 15: Homologous comparison of the altered protein. 
Letters in the rectangular box indicate the human FAM111A R569 residue. It is of note 
that R569 is not well conserved among various species.  
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Figure 16: Shared and different phenotypic features in KCS. 
Clinical features in gray-shaded rectangular boxes indicate different phenotypic features 
between KCS1 and KCS2. It is unknown whether immunodeficiency is a clinical 
feature of KCS2. 
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Figure 17: KCS and its related syndrome. 
TBCE mutation causes both KCS1 and Sanjad-Sakati syndrome, and FAM111A mutation 
causes both KCS2 and gracile bone dysplasia. These syndromes share characteristic 
three features (growth retardation, hypoparathyroidism, and skeletal defects: yellow 
letters). These syndromes could be designated as Kenny–Caffey related syndrome. 
There may be other syndrome which could be included in this entity, and there may be 
other gene which would be responsible for this entity.  
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[Abbreviations] 
 
KCS:      Kenny–Caffey syndrome 
KCS1:     Kenny–Caffey syndrome type 1 
KCS2:      Kenny–Caffey syndrome type 2 
SSS:      Sanjad–Sakati syndrome  
HRD:      Hypoparathyroidism–Retardation–Dysmorphism  
STR:      Short tandem repeat marker 
TBCE:      Tubulin-folding cofactor E 
NGS:      Next–generation DNA sequencing 
FAM111A:  Family with sequence similarity 111, member A 
AST:      Aspartate aminotransferase 
ALT:      Alanine aminotransferase 
IGF-1:     Insulin-like growth factor 1 
Ca:      Calcium 
P:     Phosphorus 
PTH:      Parathyroid hormone 
Mg:     Magnesium 
CT:      Computed tomography 
GHD:      Growth hormone deficiency 
BWA:      Burrows-Wheeler Aligner 
SNV:      Single-nucleotide variant 
PCR:     Polymerase chain reaction 
RT-PCR:    Reverse-transcribed PCR 
SNP:      Single-nucleotide polymorphism 
SIFT:     Sorting Intolerant From Tolerant 
PolyPhen:   Polymorphism Phenotyping  
LT:      Large T  
COL1A1:   Collagen type1 alpha 1 
FGFR3:    Fibroblast growth factor receptor 3 
iPS:     Induced pluripotent stem 
